Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

Invesco LLC slashed its Amgen holdings by 20.2%, unloading 2,310 shares worth roughly $2.85 million. This sale brought ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

A 333-unit community, Hillcrest Apartments, will be developed directly across from Amgen’s headquarters in Thousand Oaks, ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, prevalent gastrointestinal side effects are leading the company to use a slow | ...

Amgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...

Oppenheimer & Co. Inc. trimmed its stake in Amgen Inc. by 1.2% in Q1, selling 1,335 shares, bringing its holding to 109,833 ...

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...